Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PBMC versus PBS in women with recurrent implantation failure and low endometrial immune profile
IRCT20160422027520N29Phase 2Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- May 2026
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of peripheral blood mononuclear cells in Recurrent Implantation Failure (RIF) (2 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoints: Immune cell counts, Pregnancy rate and 3 more. Started May 2026; status: completed.
02
Drugs
peripheral blood mononuclear cells
03
Conditions
Recurrent Implantation Failure (RIF)
Beyond the preview
Go deeper on IRCT20160422027520N29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20160422027520N29.